Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy

References

• Stevenson ML, Lebwohl M. Iatrogenic effects of biologics for psoriasis. Clin Dermatol. 2011;29:614–21.
   PubMed Web of Science ®Google Scholar
• Ramirez-Fort MK, Levin AA, Au SC, Gottlieb AB. Continuous versus intermittent therapy for moderate-to-severe psoriasis. Clin Exp Rheumatol. 2013;31:S63–S70.
   PubMed Web of Science ®Google Scholar
• De Simone C, Amerio P, Amoruso G, et al. Immunogenicity of anti-TNFalpha therapy in psoriasis: a clinical issue? Expert Opin Biol Ther. 2013;13:1673–82.
   PubMed Web of Science ®Google Scholar
• Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol. 2014;170:261–73.
   PubMed Web of Science ®Google Scholar
• Mahil SK, Arkir Z, Richards G, et al. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study. Br J Dermatol. 2013;169:306–13.
   PubMed Web of Science ®Google Scholar
• Leman J, Burden AD. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis. Br J Dermatol. 2012;167:12–20.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Wan J, Callis Duffin K, et al. Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol. 2012;148:487–94.
   PubMedGoogle Scholar
• Norlin JM, Steen Carlsson K, Persson U, Schmitt-Egenolf M. Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice. Dermatology. 2012;225:326–32.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Duffin KC, Bissonnette R, et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. New Engl J Med. 2015;373:136–44.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Reich K, Lebwohl M, et al. Uncover, investigators U-. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386:541–51.
   PubMed Web of Science ®Google Scholar
• Thaci D, Humeniuk J, Frambach Y, group SS, et al. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol. 2015;173:777–87.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. New Engl J Med. 2015;373:1318–28.
   PubMed Web of Science ®Google Scholar
• Papp K, Thaci D, Reich K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015;173:930–9.
   PubMed Web of Science ®Google Scholar
• Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173:1387–99.
   PubMed Web of Science ®Google Scholar
• Schmitt-Egenolf M. PsoReg – the Swedish registry for systemic psoriasis treatment. The registry’s design and objectives. Dermatology (Basel). 2007;214:112–7.
   PubMed Web of Science ®Google Scholar
• Schmitt-Egenolf M. Psoriasis therapy in real life: the need for registries. Dermatology (Basel). 2006;213:327–30.
   PubMed Web of Science ®Google Scholar
• Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978;157:238–44.
   PubMedGoogle Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–6.
   PubMed Web of Science ®Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095–108.
   PubMed Web of Science ®Google Scholar
• Barzi S, Befrits G, Bergman B, Bruchfeld J, Ettarp L, Flytström I, et al. [Läkemedelsbehandling av psoriasis – Ny rekommendation]. Information from the Medical Products Agency. 2011;4:15–21.
   Google Scholar
• Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139:1627–32; discussion 32.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598–606.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, Investigators Ps, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665–74.
   PubMed Web of Science ®Google Scholar
• Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357:1842–7.
   PubMed Web of Science ®Google Scholar
• Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Investig Dermatol. 2005;125:659–64.
   PubMed Web of Science ®Google Scholar
• Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161:987–1019.
   PubMed Web of Science ®Google Scholar
• Andréasson S, Allebeck, P, eds. [Alkohol och hälsa. En kunskaps-översikt om alkoholens positiva och negativa effekter på vår hälsa] (In Swedish). Stockholm: Statens folkhälsoinstitut; 2005.
   Google Scholar
• Burstrom K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res. 2001;10:621–35.
   PubMed Web of Science ®Google Scholar
• Gerdes S, Zahl VA, Weichenthal M, Mrowietz U. Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology (Basel). 2010;220:38–43.
   PubMed Web of Science ®Google Scholar
• Norlin JM, Steen Carlsson K, Persson U, Schmitt-Egenolf M. Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients. Br J Dermatol. 2012;166:797–802.
   PubMed Web of Science ®Google Scholar
• Rosen CF, Mussani F, Chandran V, et al. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology. 2012;51:571–6.
   PubMed Web of Science ®Google Scholar
• Hägg D, Eriksson M, Sundström A, Schmitt-Egenolf M. The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men. PLoS One 8:e63619. doi: 10.1371/journal.pone.0063619
   PubMed Web of Science ®Google Scholar
• Langenbruch A, Radtke MA, Krensel M, et al. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol. 2014;171:1123–8.
   PubMed Web of Science ®Google Scholar
• Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005;141:1527–34.
   PubMed Web of Science ®Google Scholar
• Fortes C, Mastroeni S, Leffondre K, et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol. 2005;141:1580–4.
   PubMed Web of Science ®Google Scholar
• Lonnberg AS, Skov L, Skytthe A, et al. Association of psoriasis with the risk for type 2 diabetes mellitus and obesity. JAMA Dermatol. 2016;152:761–7.
   PubMed Web of Science ®Google Scholar
• Li W, Han J, Choi HK, Qureshi AA. Smoking and risk of incident psoriasis among women and men in the United States: a combined analysis. Am J Epidemiol. 2012;175:402–13.
   PubMed Web of Science ®Google Scholar
• Schmitt-Egenolf M. Physical activity and lifestyle improvement in the management of psoriasis. Br J Dermatol. 2016;175:452–3.
   PubMed Web of Science ®Google Scholar
• Tennvall GR, Hjortsberg C, Bjarnason A, et al. Treatment patterns, treatment satisfaction, severity of disease problems, and quality of life in patients with psoriasis in three nordic countries. Acta Dermato-Venereologica 2013;93:442–5.
   PubMed Web of Science ®Google Scholar